Role of the plasma cascade systems in ischemia/reperfusion injury of bone.
Ischemia/reperfusion (I/R) injury has been extensively studied in organs such as heart, brain, liver, kidney, and lung. As a vascularized organ, bone is known to be susceptible to I/R injury too, but the respective mechanisms are not well understood to date. We therefore hypothesized that, similar to other organs, plasma cascade-induced inflammation also plays a role in bone I/R injury. Reperfusion injury in rat tibia was induced by unilateral clamping of the femoral artery and additional use of a tourniquet, while keeping the femoral vein patent to prevent venous congestion. Rats were subjected to 4h ischemia and 24h reperfusion. Deposition of complement fragment C3b/c and fibrin as well as expression of tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and E-selectin was detected by immunohistochemistry. In plasma, the levels of high mobility group box1 (HMGB1) were measured by ELISA. The total level of complement in serum was assessed by the CH50 test. Our results show that deposition of C3b/c was significantly increased with respect to healthy controls in cortical bone as well as in marrow of reperfused limbs. C3b/c deposition was also increased in cortical bone, but not in bone marrow, of contralateral limbs. Deposition of fibrin, as well as expression of PAI-1, was significantly increased in bone after ischemia and reperfusion, whereas expression of tPA was reduced. These differences were most prominent in vessels of bone, both in marrow and cortical bone, and both in reperfused and contralateral limbs. However, PAI-1, was only increased in vessels of reperfused cortical bone and there were no significant changes in expression of E-selectin. With respect to solid bone tissue, a significant increase of C3b/c and fibrin deposition was shown in osteocytes, and for fibrin also in the bone matrix, in both contralateral and reperfused cortical bone compared with normal healthy controls. A slight expression of TF was visible in osteocytes of the normal healthy control group, while TF was not present in the experimental groups. Moreover, CH50 values in serum decreased over time and HMGB1 was significantly increased in plasma of animals at the end of reperfusion. We conclude that ischemia and reperfusion of bone leads to activation of the complement and coagulation systems and a downregulation of the fibrinolytic cascade. In the acute phase, a vascular inflammation induced by activation of the plasma cascade systems also occurs in the bone. This is similar to I/R injury of other vascularized organs and tissues.
Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; Department of Clinical Research, University of Bern, Bern, Switzerland.
Shengye
S
Zhang
Department of Clinical Research, University of Bern, Bern, Switzerland.
Carlos
C
Wotzkow
Immunology Research Centre, St. Vincent's Hospital, Melbourne, Australia.
Anjan K
AK
Bongoni
Department of Clinical Research, University of Bern, Bern, Switzerland.
Jane
J
Shaw-Boden
Department of Clinical Research, University of Bern, Bern, Switzerland.
Mark
M
Siegrist
Department of Clinical Research, University of Bern, Bern, Switzerland; Division of Plastic and Hand Surgery, Inselspital, Bern, Switzerland.
Adriano
A
Taddeo
Department of Clinical Research, University of Bern, Bern, Switzerland; Pulmonary Medicine, Bern University Hospital, Bern, Switzerland.
Fabian
F
Blank
Department of Clinical Research, University of Bern, Bern, Switzerland.
Willy
W
Hofstetter
Department of Clinical Research, University of Bern, Bern, Switzerland. Electronic address: robert.rieben@dkf.unibe.ch.
Robert
R
Rieben
D000818:Animals; D001857:Bone Matrix / Q000378:metabolism; D001842:Bone and Bones / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D003179:Complement C3b / Q000378:metabolism; D019040:E-Selectin / Q000378:metabolism; D005337:Fibrin / Q000378:metabolism; D024243:HMGB1 Protein / Q000097:blood; D006614:Hindlimb / Q000473:pathology; D008297:Male; D010011:Osteocytes / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000097:blood* / Q000473:pathology; D012756:Sheep; D013925:Thromboplastin / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D019040:E-Selectin; D024243:HMGB1 Protein; D017395:Plasminogen Activator Inhibitor 1; D003179:Complement C3b; D005337:Fibrin; D013925:Thromboplastin; D010959:Tissue Plasminogen Activator
Bone; Coagulation; Complement; Fibrinolysis; Ischemia/reperfusion injury